Filtered library · Archetype
Earnings inflection · 226 dossiers
Dossiers classified as Earnings inflection — 226 names, each with its thesis, invalidation trigger and catalyst calendar.
All 226 are dated research with a published kill line — the level named in advance that would prove the call wrong.
All dossiers IRDM Iridium Communications Inc fresh MEDIUM Iridium Communications’ merger-discount thesis depends on Rocket Lab completing the acquisition announced on 2026-06-29. The 2026-09-24 vote tests shareholder approval; completion before a weekly close below $43.50 settles the published… OSCR Oscar Health, Inc. fresh MEDIUM Oscar Health's next valuation leg needs quantified 2027 growth at its September 16, 2026 Investor Day. Confirmation requires that disclosure and a subsequent weekly close above $32.76 before a weekly close below $29.83; absence of the… CNC Centene Corporation fresh LOW Centene's margin-repair case requires sustained earnings guidance and a weekly breakout above $68.72 by its 2026-10-27 results. The 2026-09-09 daily close of $64.06 leaves continuation under pressure; a weekly close below $65 or a… APGE Apogee Therapeutics, Inc. SUPREME The all-cash takeout settled: the AbbVie merger became effective 2026-09-03 at $135.11 per share (~$10.9B equity value), trading was halted after the 2026-09-02 close of $135.07 and Nasdaq suspended the stock 2026-09-04. The leg terminated… ATAI AtaiBeckley Inc. SUPREME All named antitrust gates are retired: HSR expired 2026-08-28, the UK CMA had no further questions on 2026-08-21, Germany cleared 2026-07-30, and the ACCC's 14-day waiting period runs to 10:00 a.m. ET on 2026-09-10. Only the 2026-09-08… DSGR Distribution Solutions Group, Inc. SUPREME DSGR trades $0.34 under the $35.00 all-cash price LKCM Headwater agreed on 2026-07-16 to pay for the ~21% of the company it does not already own; the 2026-09-01 PREM14A and SC 13E-3 filings started the clock, leaving only HSR and a… ATKR Atkore Inc. HIGH Eight days to the HSR gate: notifications filed 2026-08-14 put the initial waiting period's expiry at 2026-09-14, and EDGAR still shows no definitive proxy as of 2026-09-06 — the 2026-08-28 PREM14A leaves meeting date, record date and… BWMN Bowman Consulting Group Ltd. HIGH Bowman Consulting Group’s $43.00 cash acquisition makes merger completion the central thesis. The case resolves with payment of the announced consideration before a daily close below $40.50; the 2026-09-13 go-shop deadline narrows… HZO MarineMax, Inc. HIGH Deal pin rather than a growth story: the $53.00 all-cash Safe Harbor/Blackstone Infrastructure take-private signed 2026-08-09 leaves $0.89 to terms at the 2026-09-02 close of $52.11. The gap widened from $0.80 on 2026-08-21 while no… PSNL Personalis, Inc. HIGH The MRD story has been overtaken by a live sale process: StreetInsider reported 2026-07-17 that Personalis retained Centerview, TD Securities and Cooley after takeover interest from Merck (already a >10% holder and 19% of Q1 revenue) plus… TVTX Travere Therapeutics, Inc. HIGH The FSGS/IgAN ramp story stalled rather than broke: the 2026-09-04 close of $65.28 sits 3.3% under the 2026-08-27 high of $67.52 with RSI(14) decayed from 65.6 to 56.0 and no published target change since Piper Sandler's $68 on 2026-08-17.… VREX Varex Imaging Corporation HIGH Signed all-cash takeout at $18.90 (Teledyne, 2026-08-10); the 2026-09-02 close of $18.47 leaves $0.43 of gross gap, three cents wider than on 2026-08-28. Twenty-four days past signing, EDGAR shows nothing after the 2026-08-18 Form 4 — no… ABCL AbCellera Biologics Inc. MEDIUM Post-binary shelf intact and unchanged: closes of $11.38 (08-14), $11.35 (08-28) and $11.36 (09-02) against the $9.75 follow-on price, with RSI(14) unwinding 97.4 → 52.9. The 2026-09-09 Cantor Global Healthcare presentation is the only… ABSI Absci Corporation MEDIUM Single-asset binary: ABS-201's interim hair-growth proof-of-concept is guided to 2H 2026 with no confirmed date, funded by the June 2026 $100M raise that left $201.1M at 2026-06-30 and a runway into H2 2028. Since the 2026-08-11 revenue… ALVO Alvotech MEDIUM Alvotech's recovery prices in Q4 2026 FDA approvals after the Reykjavik inspection closure announced on 2026-07-29. AVT05 and AVT06 approvals within that window would confirm the regulatory-repair case; another manufacturing-related… AMLX Amylyx Pharmaceuticals, Inc. MEDIUM The binary resolved on 2026-08-18 (LUCIDITY: 55% cut in Level 2/3 hypoglycemic events, p=0.000003) and the launch was funded at $35.50 on 2026-08-20 for ~$471.7M net. What is left is the regulatory leg — NDA guided by year-end 2026, with a… AQST Aquestive Therapeutics, Inc. MEDIUM Anaphylm's 2026-01-30 CRL was usability-scoped, and the 2026-08-10 human factors data — median pouch-opening time 3 seconds versus 17 — addresses the named deficiency, with the NDA resubmission guided into Q3 2026, a window closing… ASMB Assembly Biosciences, Inc. MEDIUM Gilead-validated antiviral: Gilead exercised the HPI license option on 2025-12-22 ($35M net fee, up to $330M milestones), Q2 beat both lines on 2026-08-13, and Assembly's 40% US cost/profit-share opt-in is due by year-end 2026. The… CDNA CareDx, Inc. MEDIUM Post-LCD repricing extended rather than stalled: the $48.61 shelf broke, a 52-week high of $52.36 printed, and the 2026-08-28 close was $49.79 — all with no company release since 2026-08-07. The 2026-08-30 LCD effective date carries only… CLYM Climb Bio, Inc. MEDIUM The 2026-09-03 CLYM116 Phase 1 read cleared: a single 320 mg dose suppressed APRIL >90% and IgA/Gd-IgA1 60–75% through 12 weeks, supporting quarterly dosing, and BTIG ($32), B. Riley ($30) and Baird ($25) re-marked within two sessions. The… CRDL Cardiol Therapeutics Inc. Class A MEDIUM Single-asset cardiology micro-cap re-rating on Phase II publication flow and Canaccord's 2026-08-17 Buy reiteration at a $10 target; the shares closed 2026-09-04 at a 52-week high of $2.20, up 103.7% in three months, and the only… FDMT 4D Molecular Therapeutics, Inc. MEDIUM Wet-AMD durability re-rating off the 2026-07-18 PRISM 2-year data (78% injection-burden reduction, 2.7 vs 12.0 projected, n=30) is cooling without news: from the 2026-08-21 close of $15.83 the shares closed $14.67 on 2026-08-28, 12.5%… FRNM Freenome, Inc. MEDIUM Freenome's approved blood-test story depends on Abbott launching SimpleScreen CRC and demonstrating reimbursed testing. Carelon's 2026-11-15 guideline strengthens the pathway; a weekly close below $14 or no US launch by 2026-12-31… MANE Veradermics, Incorporated MEDIUM Extended-release oral minoxidil story: Study '302' showed +30.3/+33.0 hairs/cm² vs +7.3 placebo at Month 6 (2026-04-27, p<0.0001), and the confirmatory Study '304' topline guided to 2H26 is the binary. The 2026-09-04 close of $98.51 sits… MGNX MacroGenics, Inc. MEDIUM MGC026's head-and-neck cohort cleared its pre-specified Stage 1 threshold on 2026-07-23 and the interim Phase 1 data lands as ESMO poster 1020P on 2026-10-23; the name walks in with $327M pro forma cash (2026-06-30) built from the Bora… NAVN Navan, Inc. MEDIUM Q2 FY2027 prints 2026-09-09 with the first positive non-GAAP operating-income guide ($13.5–14.5M) on the line. Four target raises in 21 days — BofA $26→$34 on 09-02, Morgan Stanley $33 on 09-04 — landed while the shares fell from the… ORKA Oruka Therapeutics, Inc. MEDIUM Supply overhang cleared: the 2026-07-01 Fairmount $300M block at $84.43 was absorbed and price closed $92.70 on 07-17 (+11.6%), 5% off the 52-week high, with 19.85% short interest still rising. Long-acting I&I re-rated by the $10.9B… PLSE Pulse Biosciences, Inc MEDIUM Timeline-compression leg still printing highs on thinning inputs: the 2026-09-02 close of $52.68 is a fresh 52-week high, but RSI(14) fell to 73.2 from 82.5 at the 2026-08-21 high and no company disclosure has landed since the 2026-08-06… SLDB Solid Biosciences Inc. MEDIUM Post-Sarepta DMD vacuum trade still in its waiting phase, with the sell-side moving before the company does: no release since the 2026-08-06 Q2 print, but Truist carried Buy/$20 on 2026-08-21 and Cantor raised to $26 on 2026-08-27. The… TNET Trinet Group, Inc. MEDIUM Post-print durability leg: after the 2026-07-30 Q2 beat (ICR 86% vs 90%, adj EPS $1.55 vs $0.93) and FY guide raise, TNET closed 2026-08-28 at $70.27, 2.0% under its $71.67 high. UBS lifted its target to $71 on 2026-08-24 but the… VSTM Verastem, Inc. MEDIUM Post-Q2 re-rate extended rather than stalled: $6.89 on 2026-08-21 to $8.02 on 2026-09-02, RSI(14) 71.4, with no new company disclosure located in that window beyond a 2026-09-02 conference notice. The 2026-08-28 Oberland closing date has… XNCR Xencor, Inc. MEDIUM Two overhangs closed in three weeks: the $105M Alexion settlement (2026-07-29) ended the Ultomiris dispute and pushed runway through 2028, and Q2 revenue of $51.2M vs $18.9M consensus (2026-08-05) drew three price-target raises on 08-06.… ZLAB Zai Lab Limited MEDIUM Re-rating from China in-licensing platform to global originator on zocilurtatug pelitecan, the internal DLL3 ADC: the 2026-08-03 FDA orphan-drug grant in neuroendocrine carcinomas and Citi's 2026-08-07 raise to $45 extended the leg, and… AAPL Apple Inc. LOW July's rotation-crown has slipped — Polymarket now gives Apple 20% odds of ending 2026 as the largest company (7/24) and semis are breaking out again (NVDA 7/23). The live narrative is the 'anti-CapEx AI trade' as Alphabet turns… ASTS AST SpaceMobile, Inc. LOW The 2026-09-02 close of $62.40 reclaimed the $56 shelf breached one session earlier, driven by a Berenberg Buy initiation at $92 and a director's 2026-08-31 open-market purchase of 10,822 shares — neither a company disclosure. Spectrum… BBNX Beta Bionics, Inc. LOW The post-2026-07-29 re-acceleration leg has stalled at consensus: $19.42 on 2026-09-04 versus $19.72 on 2026-08-28, RSI(14) cooling 71.7 to 62.7, against a 12-analyst average target of $20.31. Into that stall the CMO and CEO sold on… BLSH Bullish fresh LOW Bullish's regulatory repricing thesis requires successful CLARITY Act cloture followed by a weekly close above $37.10 before a weekly close below $31. The September 15, 2026 milestone is motion ripening, while the September 9 close of… BMEA Biomea Fusion, Inc. LOW Icovamenib's beta-cell-preservation story got a dated readout when COVALENT-211 completed enrollment on 2026-08-24, but the same release pushed 26-week topline to Q1 2027 — against $35.2M cash at 2026-06-30, runway into Q2 2027 and… BTGO BitGo Holdings, Inc. LOW Broken IPO that cleared its 2026-07-21 lockup without a supply flood but is grinding on the $4.665 all-time low with no bounce; Goldman cut its target to $7.75, and the undated $100M Galaxy verdict plus the ~2026-08-26 Q2 print are the… CADL Candel Therapeutics, Inc. LOW Pre-BLA re-rating is cooling rather than breaking: shares quoted $12.78 on 2026-09-05 against the $13.75 52-week high and the 2026-08-28 close of $13.07, with no company data since the 8/13 Q2 print. Three CEO firesides (09-09, 09-10,… CRCL Circle Internet Group, Inc. fresh LOW Circle Internet Group's Arc-led infrastructure breakout failed when its 2026-09-09 close of $92.99 breached the published $95 boundary. The scheduled 2026-09-16 public launch still tests delivery, while any recovery case requires renewed… DTIL Precision BioSciences, Inc. LOW First clinical evidence that a gene editor removes hepatitis-B cccDNA (EASL late-breaker, 2026-05-27, <1% remaining in one biopsy) is the whole story; the shares closed $7.47 on 2026-09-04, 19.5% under the $9.28 52-week high, with no… IMMX Immix Biopharma, Inc. LOW Single-asset CAR-T regulatory story now inside its own event window: the 95% CR (19/20) from 2026-05-21 is the bar the late-September NEXICART-2 update must clear on a bigger denominator. The 2026-09-02 close of $13.96 is 3.5% under the… INBX Inhibrx Biosciences, Inc. fresh LOW Inhibrx Biosciences’ advance prices HexAgon clinical success and a Phase 3 start within the guided quarter. The 2026-09-08 results and September start confirmation test that case; a weekly close below $104 or reported primary-endpoint… IONQ IonQ, Inc. LOW The missing forward number is the story: no Q3 range and a $280–290M FY guide that excludes SkyWater have left IonQ unbenchmarked since 2026-08-05, and the 2026-09-08 NYSE Investor Day is the dated venue where combined guidance is… KURA Kura Oncology, Inc. LOW The binary already fired: KOMZIFTI's 2025-11-13 approval and ~40% R/R NPM1 share are priced, and the $24–28 targets need a frontline Phase 3 that doesn't read until 2028. The tape is drifting — $10.39, lower third of the H1 range. A… NVAX Novavax, Inc. LOW Novavax's Matrix-M royalty re-rating needs company-confirmed Sanofi trial timing at the 2026-09-09–2026-09-10 conferences. The near-term case fails if both pass without that timing or a weekly close falls below $9.00. OKLO Oklo Inc. LOW Three straight cohort-driven sessions carried OKLO from the 2026-07-29 close of $36.84 to $43.33 on 2026-08-04, with no Oklo release behind any of them. The 2026-08-07 Q2 call is the binary. PANL Pangaea Logistics Solutions Ltd. fresh LOW Dry-bulk recovery is in the P&L but not the tape: Q1 2026 (2026-05-11) adjusted EBITDA +70% YoY to $25.2M on $15,252/day TCE, yet the stock closed $7.42 on 2026-08-07, 20.1% under the $9.29 52-week high. The 2026-08-10 Q2 print is the… PL Planet Labs PBC LOW The 9/2 close of $19.99 reclaimed the $19.83 July range top and held about 4% above the $19.16 range low with RSI(14) at 13.2, but everything still rests on the 9/3 Q2 FY27 print against a $102–107M guide unrevised since 6/4. Options… RIVN Rivian Automotive, Inc. LOW Post-binary delivery arithmetic: the raised 65,000–70,000 FY guide needs 42,441–47,441 H2 units against 22,559 delivered in H1, while the R2 second shift (2026-09-30) is not material until Q4. The 2026-09-03 close of $15.91 sits 41 cents… RPD Rapid7, Inc. LOW The post-Q2 cost-out re-rating broke: back-to-back macro sessions on 2026-09-01 (-9.7%) and 2026-09-02 (-7.8%) returned RPD to a $11.00 close on 2026-09-04, through the $11.20 level this coverage published as the break condition and back… SLN Silence Therapeutics Plc LOW First-in-class siRNA re-rated on the 2026-08-10 SANRECO readout (88% response vs 19% placebo, n=48) and immediately funded with a ~$175M raise priced at $13.50/ADS; with Phase 3 not starting until 1H 2027, the equity now trades on… SMMT Summit Therapeutics Inc. fresh LOW Class-validation leg reaccelerating: Akeso's 2026-09-02 HARMONi-2 interim showed a statistically significant OS win over pembrolizumab monotherapy, and 2026-08-25's HARMONi-GI1 was the first Phase III win outside NSCLC. The 2026-09-04… SMR NuScale Power Corporation LOW SMR closed 2026-09-02 at $9.56, back near the top of the band between the 2026-08-18 close of $8.64 and the 2026-08-25 close of $9.81 — lifted by a sector-wide nuclear bid (Oklo +2.57%) rather than company news, a session after its own… UPXI Upexi, Inc. LOW Upexi’s Solana-discount recovery requires positive audited net assets and a Nasdaq bid-price cure. The September 28 annual-report checkpoint is provisional, while a weekly close below $1.00 invalidates the recovery structure. VSH Vishay Intertechnology, Inc. LOW Cycle-turn re-rate has fully round-tripped: down ~46% from $69.47 to the high-$30s, now under the $50 June placement and below every covering analyst's target. Q1's 1.34 book-to-bill and $1.6B backlog were real but sit at ~35x forward into… YSS York Space Systems Inc. LOW Two Space Force selections — the 2026-08-18 NITE-STAR IDIQ pool and the 2026-08-25 Space Data Network Backbone award ($12M, one of five equal awards in a $60M pool) — landed and the tape still closed lower at $8.97 on 2026-08-28, a… ALOT AstroNova, Inc. SUPREME Closed situation: Arcline's $29.00 all-cash take-private completed 2026-08-26, shares converted to cash and Nasdaq trading ended, with Nasdaq's Form 25-NSE filed the same day and no Form 15 on EDGAR as of 2026-09-06. The final $28.99 close… AVNS Avanos Medical, Inc. SUPREME Closed record, not a live setup: AIP's $25.00/share all-cash take-private completed 2026-07-27 (EV ~$1.272B), AVNS left the NYSE that day, and the 2026-08-06 Form 15-12G — one holder of record — suspended SEC reporting. Nothing is dated… CBZ CBIZ, Inc. SUPREME Completion-and-clock trade now: the 2026-09-04 close of $54.85 sits $0.15 under signed $55.00 all-cash terms, in from $0.34 on 2026-08-21, after the go-shop lapsed 2026-08-27 and the same-day PREM14A disclosed 24 parties contacted, six… CCRN Cross Country Healthcare, Inc. SUPREME Terminated rather than live: the Knox Lane take-private closed 2026-07-21 at $13.25 cash, Nasdaq filed Form 25 that day, and the Form 15-12G/A of 2026-07-31 certifies approximately one holder of record. EDGAR has recorded no filing for the… CNTA Centessa Pharmaceuticals plc SUPREME Closed cash-plus-CVR takeout; nothing trades. Lilly's UK scheme ($38.00 cash plus a non-transferable CVR of up to $9.00) went effective 2026-06-24, Form 15-12G dated 2026-07-06. Since the last note the only motion is registry-side:… CRNX Crinetics Pharmaceuticals, Inc. SUPREME The settlement claim resolved: the Vertex merger became effective 2026-09-01 at $85.00 a share in cash, Nasdaq trading was suspended before that day's open and a Form 25 was requested. The final print is $84.95 on 2026-08-31; shares are… FBRX Forte Biosciences, Inc. SUPREME The spread paid as contracted: argenx reported 19,894,879 shares tendered (~87.13%) at the 2026-08-26 expiration, completed the back-end merger at $77.00 cash on 2026-08-27 and ended the Nasdaq listing. The final print was $76.99, a cent… GBTG Global Business Travel Group, Inc. SUPREME Take-private in its last mile: stockholders adopted the $9.50 Long Lake merger on 2026-08-03 and the 2026-09-04 close of $9.48 leaves $0.02 gross against the unaffected $5.93. Only undated offshore clearances stand before the 2026-11-02… KALV KalVista Pharmaceuticals, Inc. SUPREME Resolved cash takeout, not a live security: Chiesi's $27.00/share acquisition closed 2026-06-11 and KALV stopped trading on Nasdaq that morning. An EDGAR check on 2026-09-05 shows no issuer filing since the 2026-08-14 Schedule 13G/A… LPRO Open Lending Corporation SUPREME Terminal and now deregistered: ANV's $3.15 all-cash tender took ~85.65% by 2026-07-27, the §251(h) merger closed 2026-07-30, Form 25-NSE went in the same day and Form 15-12G on 2026-08-10. Last public close $3.14 on 2026-07-29. Nothing… NUVL Nuvalent, Inc. SUPREME No tradable NUVL equity exists: GSK's $124 all-cash deal completed 2026-07-15, trading was suspended, and a Form 15-12G filed 2026-07-27 lists an approximate holder-of-record count of one. The 2026-09-18 zidesamtinib PDUFA still on some… OLPX Olaplex Holdings, Inc. SUPREME Closed by event and unchanged since: Henkel's all-cash takeout completed 2026-07-07 at $2.06 per share, Nasdaq delisting and a Form 15-12G followed, and Henkel's IR calendar now dates the first consolidated period containing the brand to… PAYO Payoneer Global Inc. SUPREME Merger-arb into a dated gate: the 2026-09-14 special meeting is eight days out, HSR early termination was granted 2026-07-28, and the 2026-09-04 close of $7.17 leaves $0.23 to Nuvei's $7.40 all-cash offer — the tightest spread since… TBRG TruBridge, Inc. SUPREME Closed and deregistered — the IKS Health merger paid $26.25/share cash at the 2026-07-09 effective time, Form 25 the same day, Form 15-12G on 2026-07-24, and the adjusted series stops at $26.24 on 2026-07-08. The only live thread is a… ABVX Abivax SA HIGH Nine weeks of silence since the 2026-07-30 FDA pre-NDA alignment ended in stabilisation rather than a lower low — the 2026-09-04 close of $114.79 with RSI(14) back to 38.8 from 23.7 on 2026-08-28, still under the $125.00 placement price.… ARX Accelerant Holdings HIGH Fixed-price take-private: $20.25 all-cash from Thoma Bravo, with the 2026-09-04 close of $19.88 leaving a $0.37 gross spread on an insurance-regulatory calendar guided to H1 2027. The spread has tightened from $0.66 on 2026-08-21 on an… ESPR Esperion Therapeutics, Inc. HIGH Resolved and off the tape: the ARCHIMED take-private closed 2026-07-13 at $3.16 cash plus a non-transferable CVR of up to $100M, and Esperion filed a Form 15-12G on 2026-07-23 to suspend Exchange Act reporting. The last listed close was… ITGR Integer Holdings Corporation HIGH Signed-deal instrument since 2026-08-03: KKR's $127.00 all-cash agreement leaves $1.67 above the 2026-08-28 close of $125.33. Four weeks after signing, no merger proxy is on file and no HSR filing date has been disclosed, so a year-end… MKTX MarketAxess Holdings, Inc. HIGH ICE's $167.00 all-cash deal (signed 2026-07-30) leaves MKTX trading purely as a spread: $167.00 less the 2026-08-28 close of $162.72 is $4.28 gross, in from $4.89 a week earlier. ICE's $3.75B bond pricing on 2026-08-11 took the financing… OGN Organon & Co. HIGH Deal-pinned arbitrage with no discretionary leg left: the $14.00 all-cash Sun Pharma merger was approved by holders 2026-07-23, and the 2026-09-04 close of $13.78 leaves $0.22 gross into a stated early-2027 completion against a 2027-01-26… PEB Pebblebrook Hotel Trust HIGH The August overheat has drained without a break: the 2026-09-04 close of $18.03 sits 8.7% under the 52-week high with RSI(14) at 48.1, versus 73.3 on 2026-08-28, while the 16-desk consensus target edged to $19.12. No rating action since… PVLA Palvella Therapeutics, Inc. HIGH The undated FDA window closed on 2026-08-31: the rolling NDA for QTORIN rapamycin in microcystic lymphatic malformations is complete under 505(b)(2), starting a 60-day agency clock on filing acceptance and the Priority Review decision that… RAMP LiveRamp Holdings, Inc. HIGH Shareholder gate cleared 2026-08-17 (51,578,202 for / 60,073 against), leaving CFIUS, HSR and non-US clearances as the only open conditions on Publicis' $38.50 cash offer. The 2026-09-04 close of $37.75 is $0.75 under contract, tighter… SAFT Safety Insurance Group, Inc. HIGH The Mapfre $105.00 all-cash deal finally has filed dates: HSR filings made 2026-08-13 with the initial waiting period expiring 2026-09-14, a Massachusetts Form A filed 2026-08-25, and a preliminary proxy filed 2026-09-03 that still leaves… SMTI Sanara MedTech Inc. HIGH Merger-arb instrument since MIMEDX's 2026-07-29 agreement ($33.00 cash + 0.4735 MDXG per share). A Form S-4 now appears on EDGAR under MIMEDX's CIK with a 2026-08-24 consent exhibit, moving the deal into its documented phase; at the… TECH Bio-Techne Corp HIGH Merger arb pinned 57 cents under Merck KGaA's $73.00 cash bid: the 2026-09-23 special meeting is dated, and the HSR clock restarted by the 2026-08-19 refiling should lapse around 2026-09-18, with no FTC clearance and no second request… UTZ Utz Brands, Inc. HIGH The 2026-08-24 preliminary merger proxy filled the one gap in the prior read: Intersnack's $14.25 all-cash take-private now has a filed Schedule 14A, and the 2026-08-28 close of $14.20 leaves $0.05 of gross spread to a company-guided Q4… VRNS Varonis Systems, Inc. HIGH The June take-private option now has a named counterparty: Reuters, Bloomberg and the WSJ reported on 2026-09-02 and 2026-09-04 that Thoma Bravo-owned Proofpoint is in advanced talks to buy Varonis, and the session needed a circuit-breaker… ACB Aurora Cannabis Inc. MEDIUM The 2026-09-02 directors' circular came and went as a unanimous rejection with no raise, and Curaleaf reaffirmed 0.3463 shares plus US$0.75 cash the same day. The 2026-09-04 close of $3.95 sits just under the announced US$4.00, so the… AGIO Agios Pharmaceuticals, Inc. MEDIUM Mitapivat sickle-cell label-expansion binary into the 2026-11-01 PDUFA, funded by a real ramp (Q2 mitapivat revenue $44.7M vs $26.03M consensus, 2026-07-30). Nothing company-dated has landed since; the tape closed $33.10 on 2026-09-04… ANRO Alto Neuroscience Inc. MEDIUM Precision-psychiatry re-rate now running on flow alone: no company news since the 2026-08-27 CFO promotion, no new sell-side revision since H.C. Wainwright's $55 on 2026-08-17. The 2026-09-04 close of $35.55 sits 3.0% under the $36.64… AVLN Avalyn Pharma Inc. MEDIUM Post-IPO inhaled-antifibrotic re-rating rebuilt to the 2026-09-04 close of $37.39 from the 2026-08-28 close of $34.69 with no company disclosure since the 2026-08-24 ERS notice; the 2026-09-07 posters carry no FVC data, leaving the… AVTX Avalo Therapeutics, Inc. MEDIUM Post-LOTUS consolidation is grinding: the 2026-09-04 close of $19.23 is 1.8% under 2026-08-28 with RSI(14) at 44.6, and the only new company news since the Q2 print is a September conference slate (2026-09-03) plus 78,000 inducement… BHVN Biohaven Ltd. MEDIUM The 2026-08-26 SK Biopharmaceuticals licence — $400M upfront, up to $150M milestones, mid-teens-to-low-twenties US royalties on opakalim — replaced the financing overhang with funded optionality, and the stock re-rated 13% that day to… BOLD Boundless Bio, Inc. MEDIUM Merger-arb wrapper on a cash shell: a planned $44–48M pre-close cash dividend plus a 3.69% stub in the AATD base-editing NewCo. Eleven weeks after the 2026-06-23 announcement the Form S-4 is still absent — EDGAR's latest filing of any kind… CCC CCC Intelligent Solutions Holdings Inc. MEDIUM Cheap, high-margin insurtech SaaS put in play: a Morgan Stanley-run sale process plus a fresh Elliott activist stake. Shares popped ~13% to ~$6 on the 2026-07-09 Reuters report yet still sit below a plausible PE take-out. The trade is… CGEM Cullinan Therapeutics, Inc. MEDIUM CD19 T-cell-engager-in-autoimmune narrative re-rated CGEM ~3x off the $5.68 low on CLN-978 lupus/RA single-dose remissions; now drifting to ~$17.10 in a bull flag under the $19.43 high with the big data catalyst spent and no dated readout… CMPS COMPASS Pathways Plc MEDIUM Clinical binary resolved 2026-07-07; what trades now is regulatory execution — rolling NDA completion guided Q4 2026, H1 2027 launch, $433.3M cash into 2028. The 2026-09-14 FDA hearing on supervised psychedelic administration is the only… DRTS Alpha Tau Medical Ltd. MEDIUM Head-and-neck re-acceleration: a 2026-06-23 first-ex-US glioblastoma treatment drove a +17.9% breakout to new 52-week highs (~$12.56 on 7/11), reclaiming the $11.99 Tolmar equity shelf. The 2026-07-21 AHNS podium with complete Alpha DaRT +… DSGN Design Therapeutics, Inc. MEDIUM Frataxin-protein-surrogate leg: RESTORE-FA's primary endpoint is now blood FXN protein change, and Larimar's FDA alignment on skin FXN as a surrogate for accelerated approval gives that path an external precedent. The company has issued… DYN Dyne Therapeutics, Inc. MEDIUM Nothing company-dated until the ~late-October Q3 print, leaving a maturing narrative to trade on small-cap biotech flow ahead of the 2027-01-21 PDUFA. ELF e.l.f. Beauty, Inc. MEDIUM Sell-side flipped from cutting to marking up in ten days — five PT raises 2026-07-10→07-17 (JPM $94, Canaccord $97, Citi $92, RJ $87, UBS $80) on the e.l.f. Hair launch and Rhode scaling, while the stock slipped to $72.25. Narrative… EPC Edgewell Personal Care Company MEDIUM Two legs — a refused $30 take-private (2026-06-22) and a first positive organic quarter (fiscal Q3 +1.1%, adjusted EPS $0.72 vs $0.62) — hold the shares 2.7% under the $29.66 high at the 2026-09-04 close of $28.87. Seventy-four days on… GERN Geron Corporation MEDIUM The leg is a self-funding commercial ramp, not the myelofibrosis binary: Q2 RYTELO revenue $57.5M (+11% QoQ), quarterly cash draw down to ~$14M on $326.9M, FY guide $220–240M reiterated at the mid-to-high end. The 2026-09-02 release added… GHRS GH Research PLC MEDIUM Eli Lilly's up-to-$3.8B AtaiBeckley buy (2026-07-16) put a large-cap price on 5-MeO-DMT for depression; GHRS is now the last independent pure-play, with best-in-class inhaled GH001 Phase 2b data, that the sector is repricing as the next… HPP Hudson Pacific Properties, Inc. MEDIUM Refinancing binary now ten days out: the 10-Q (2026-08-10) fixes the Hollywood Media Portfolio loan maturity at 2026-09-09 with the longer-term extension unresolved. The equity gave back the post-print move — $14.50 on 08-21 to $13.14 on… IDYA IDEAYA Biosciences, Inc. MEDIUM Three legs now: the darovasertib NDA under FDA RTOR guided complete H2 2026, the Genentech MTAP/PRMT5 tie-ups, and — new on 2026-08-31 — an FDA-agreed Phase 3 design for IDE849 in ES-SCLC. The 2026-08-31 and 2026-09-01 headlines did not… IKT Inhibikase Therapeutics, Inc. MEDIUM The stalled leg resolved upward on no news: IKT closed $2.50 on 2026-09-04 against a fresh 52-week high of $2.52, with RSI(14) back to 57.5 from 44.9 on 2026-08-28 and still no press release after the 2026-08-11 Q2 report. A single-asset… IMVT Immunovant, Inc. MEDIUM Single-asset FcRn story: batoclimab was discontinued after the 2026-04-02 TED Phase 3 miss, leaving IMVT-1402 plus $797.8M cash (2026-06-30) and two undated 2H CY2026 readouts (D2T RA topline, CLE proof-of-concept) ahead of 2027… IVA Inventiva S.A. MEDIUM The 30-day news blackout broke: the 2026-09-02 last-patient-last-visit release in NATiV3 (1,419 patients) reaffirmed Q4 2026 topline and closed the trial-conduct timing gate, leaving database lock and unblinding as the only steps before… JBIO Jade Biosciences, Inc. MEDIUM The July shelf near $21 broke: the 2026-09-04 close was $19.90 with RSI(14) at 24.2, and the decline from the 2026-08-21 close of $21.34 came with no Jade filing after 2026-08-14 and no release beyond the 2026-09-01 conference notice. Four… LBRX LB Pharmaceuticals Inc MEDIUM Single-asset schizophrenia binary where the sell-side keeps marking up behind a flat tape: H.C. Wainwright went $45→$60 on 2026-08-24, lifting the eight-analyst average to $53.38 against a 2026-08-28 close of $47.73, while RSI(14) cooled… MESO Mesoblast Limited MEDIUM FY2026 printed 2026-08-27 — revenue US$120.3M vs US$17.2M, net loss down 44% to US$57.5M, cash US$103M — and the ADR still closed $17.32 on 2026-09-04, capped by the 2026-07-15 high of $18.07. The catalyst the July leg leaned on has… MGTX MeiraGTx Holdings plc MEDIUM The $400M Oberland royalty deal (2026-07-07) took dilution and runway risk off the table and spiked MGTX to a new 52-week high of $15.35 before a fade to ~$12.44 — a non-dilutive re-rate of a three-program AAV gene-therapy pipeline, but… MIRM Mirum Pharmaceuticals, Inc. MEDIUM Rare-disease franchise ran to a $125 ATH on FOP data, then cooled ~9% into a confirmed 2026-07-30 Q2 print. Base compounds (Q1 sales +43% YoY, FY guide $660–680M) with FOP PDUFA 2026-09-26 and HDV Phase 3 topline 2H26 stacked ahead — but… MNPR Monopar Therapeutics Inc. MEDIUM The rolling-NDA leg rebuilt without news: $107.72 on 2026-08-21 to $117.56 on 2026-09-04, back within 5.1% of the $123.84 high, on no company release since 2026-08-19 and with two directors selling into $109–$113 on 2026-08-25 and… NGNE Neurogene Inc. MEDIUM Rett gene-therapy story stays fully financed (~$360.2M pro forma, runway into Q1 2029) and clean at 1E15 vg across N=35 at the 2026-08-10 cutoff. The 2026-09-09 IRSF community webinar is the only company-dated appearance before the… NKTR Nektar Therapeutics MEDIUM M&A read-through re-accelerating: AbbVie's $10.9B Apogee buyout (June 22, 2026) reframed NKTR as the next takeout-able Treg-IL-2 atopic-dermatitis asset, driving a ~25% run off the June low to ~$70. It's sympathy optionality, not fresh… NTSK Netskope, Inc. MEDIUM Post-lockup repair leg extended on price, not on estimates: $15.09 on 2026-08-28 vs $14.51 on 2026-08-21, while the consensus target crept only $17.25 → $17.36.P. Morgan's 2026-08-26 raise stopped at $16, below the mean. The 2026-09-02 Q2… NVCR NovoCure Limited MEDIUM Post-TRIDENT commercial-inflection leg still carried by the 2026-07-23 Q2 print (rev $183.584M vs $172.437M cons., first positive adj. EBITDA $10.8M, FY guide $710–725M). Price $17.94 on 2026-09-04 is 10.3% under the $19.99 high and held… ODTX Odyssey Therapeutics, Inc. MEDIUM First-in-class oral RIPK2 inhibitor OD-001 re-rated the story: 27% clinical remission / 61% response in Phase 2a UC (April 2026 topline), $433.1M cash into 2H 2028, and a first initiation at Buy/$44 on 2026-08-27. Price ran 68% in three… PESI Perma-Fix Environmental Services, Inc. MEDIUM Post-award drift with no new information: the shares closed 2026-09-04 at $18.70, 3.8% under the $19.43 52-week high, recovering from $17.30 on 2026-08-21 with zero company disclosure since 2026-08-12. The 2026-09-30 funding lapse was… PGEN Precigen, Inc. MEDIUM PAPZIMEOS launch-ramp durability is the binary — the first FDA-approved RRP therapy printed $21.6M net product revenue in Q1 2026, and the now-confirmed Aug 4 Q2 print (announced Jul 21) grades whether the ramp compounds sequentially or… PTGX Protagonist Therapeutics, Inc. MEDIUM De-risked dual-royalty story accelerating into a binary: icotrokinra (oral IL-23, J&J) already approved and paying 6–10% royalties; rusfertide (PV, Takeda) into a Q3 2026 PDUFA. Stock at a fresh ATH ($143.29, Jul 20) as the PV theme runs —… RAPP Rapport Therapeutics, Inc. MEDIUM RAPP broke to all-time highs at $42.62 (2026-07-17, +6.2%) on zero company news — the move is pure sell-side re-rating (BTIG reiterated Buy/$65 on 7/16, consensus PT $56.64, 12 desks Strong Buy) with Phase 3 FOCUS now enrolling globally.… RCKT Rocket Pharmaceuticals, Inc. MEDIUM Price has stalled where the 2026-08-03 safety leg left it — $3.86 on 2026-09-04, unchanged from the 2026-08-28 close — with no company disclosure since the 08-10 Q2 print and three Form 144 sale notices filed 08-18. Two webcast fireside… RLYB Rallybio Corporation MEDIUM The S-4/A filed 2026-08-26 marks Rallybio Net Cash at ~$82.2M as of 2026-08-15 but still leaves the record date and meeting date blank, so no timetable is public. The cash discount stays inverted while burn runs and the clock has no fixed… RMAX Re/Max Holdings, Inc. MEDIUM Merger arb that finally got a date. DOJ granted HSR early termination 2026-07-13 and both special meetings are set for 2026-08-14, removing the regulatory leg. RMAX $11.10 vs ~$11.86 blended (5.150 REAX at $2.21 plus the prorated $13.80… SNDX Syndax Pharmaceuticals, Inc. MEDIUM Menin-inhibitor commercial ramp accelerating: Revuforj + Niktimvo franchise cleared $100M/quarter with revenue +224% YoY, and the leg being bought is frontline AML label expansion (~10x TAM). Stock coils below 52-week-high resistance… SYNA Synaptics Incorporated MEDIUM Standalone story ended at the 2026-06-25 all-stock takeout; At the 2026-09-04 closes the gross discount compressed to ~1.4% (1.350 × $74.38 = $100.41 vs $98.99), a fourth consecutive tightening mark, while EDGAR showed no S-4 amendment as… TRVI Trevi Therapeutics, Inc. MEDIUM Second breakout leg confirmed: TRVI cleared the June $18.17 all-time high and printed $20.22 on a +9.85% July 17 session (8.3M shares, $19.07 close), lifting the tape ~+45% in six weeks on Phase 3 launch mechanics and institutional… ULCC Frontier Group Holdings, Inc. MEDIUM Fuel-relief leg replaced by an earnings-delivery leg: the 2026-07-29 Q2 print put adjusted EPS at $(0.10) against a $(0.60)–$(0.45) May guide on record $1,279M revenue, and guided 2H to breakeven-or-better. The catch is that guide assumes… USO United States Oil Fund, LP MEDIUM The driver rotated: Rubio's 2026-08-25 shift from strikes to sanctions drained the escalation bid, but EIA's 0.095M bbl crude build vs 1.600M expected (08-26) and oil rigs -5 to 447 vs 454 est (08-28) carried USO to $129.70. The narrative… VIOT Viomi Technology Co., Ltd MEDIUM Compliance-clock recovery: after the 2026-07-22 Nasdaq sub-$1 deficiency notice, the ADSs closed 2026-09-04 at $1.14, and 10 consecutive closes at or above US$1.00 convert the deficiency into a written compliance confirmation before the… WDAY Workday, Inc. MEDIUM The 2026-08-27 print removed the fundamental leg of the bear case — cRPO +14.2% inside the guided 13.5–14.5% band, FY27 margin guide lifted to 31.0%, a new $4.0B buyback — while the Q3 cRPO guide of 11–12% sits under the ~13.3% consensus.… ZBIO Zenas BioPharma, Inc. MEDIUM First-in-disease B-cell modulator: obexelimab BLA (IgG4-RD, 56% flare cut, HR 0.44) hit the FDA 2026-05-28, and the ~60-day filing determination — acceptance plus a possible Priority Review grant — is due within days, a fresh near-term… ZURA Zura Bio Limited MEDIUM Pipeline-breadth re-rating still unpaid: the 2026-08-11 Q2 print added polymyalgia rheumatica as a third tibulizumab indication and Wedbush ($22) plus Guggenheim ($20) re-rated on 2026-08-12, yet the 2026-08-28 close of $5.72 sits 18.8%… ZYME Zymeworks Inc. MEDIUM The 2026-08-25 FDA approval of Ziihera in first-line HER2+ gastroesophageal cancer converts Zymeworks from a burn-funded developer into a milestone-and-royalty recipient — a $250M payment from Jazz against $322.5M of cash at 2026-06-30,… ABEO Abeona Therapeutics Inc. LOW The post-print drift has continued without repair: the 2026-08-28 close of $5.92 sits two cents above the $5.90 shelf the prior note named as the break, with RSI(14) at 21.8 and no Abeona press release at all between 2026-08-13 and… ACDC ProFrac Holding Corp. LOW Brent pushed above $96 on 2026-09-03 as the US resumed strikes on Iran and Hormuz transit fell to roughly 4.9 mb/d, yet ACDC closed $5.15 on 2026-09-04, still under its 2026-08-14 close of $5.37. The crude-beta leg has now failed on two… ACLS Axcelis Technologies, Inc. LOW Axcelis has stopped falling without being re-bid: $115.57 on 2026-08-28 to $115.08 on 2026-09-04, RSI(14) down to 22.0, 39.9% under the $191.6 high. What is left is a de-rated implant franchise plus an undated China SAMR ruling into the… AIRO AIRO Group Holdings, Inc. LOW The drone-tariff leg failed on its own date: Section 232 took effect 2026-09-03 but Blue UAS-listed products got a 180-day deferral to ~2027-02-09, and price broke the $8.00 level to close $7.40 on 2026-09-04 with RSI(14) at 25.1. What is… AKBA Akebia Therapeutics, Inc. LOW VOICE outcomes win (USRC trial stopped early, June 2026) de-risked Vafseo's dialysis-anemia case, but the tape bled to ~$1.22, only ~48% above the $0.82 low and still fading; the late-July/early-August Q2 print is the binary —… ALHC Alignment Healthcare, Inc. LOW Profitable-MA-disruptor narrative broke on 2026-07-08: a whistleblower suit from a former Chief Transformation Officer alleges the +88% adjusted-EBITDA inflection was manufactured by reclassifying opex as capex across FY2024-25. Shares… ALMS Alumis Inc. LOW The lupus leg is gone: LUMUS missed BICLA at Week 48 and every secondary in the overall 408-patient population on 2026-09-01, and the stock closed 2026-09-04 at $11.10 with RSI(14) at 18.2, 63.4% below the $30.30 high. What is left is a… ANAB AnaptysBio, Inc. LOW Single-question Chancery stub: the next dated docket step is the defendants' answering brief on 2026-09-25, while June-quarter results are still absent from the public record through 2026-09-06 and momentum has decayed — RSI(14) 38.7 at… ARCT Arcturus Therapeutics Holdings Inc. LOW Platform-repossession re-rating extended: the CSL exit returned global KOSTAIVE plus flu/RSV/EBV rights with $12M cash and ~$16M of released liabilities against $191.5M cash, and the shares have run 95.5% in three months to a 2026-08-28… AVXL Anavex Life Sciences Corp. LOW The two overhangs cleared — both delinquent 10-Qs filed 2026-08-28, Nasdaq compliance confirmed 2026-09-02 — and the shares still fell from $3.24 on 2026-08-21 to $2.86 on 2026-09-04. What is left is the 2026-09-24 contested vote: PVG's… BAK Braskem S.A. LOW The subsidiary perimeter resolved first: Braskem Idesa's prepackaged Chapter 11, filed 2026-08-17 in SD Texas, cuts over US$920M of debt and leaves existing shareholders one-third of reorganized equity, with a combined disclosure-statement… BCAX Bicara Therapeutics Inc. LOW Bifunctional EGFR/TGF-β narrative in HPV-negative head & neck cancer stalled after the ASCO 2026 three-year-OS re-rate: $27.76 close is ~10% off the $30.99 high on roughly half prior turnover, consensus PT ~$31.46 sits only 13% above spot,… BIOA BioAge Labs, Inc. LOW ESC Congress came and went 2026-08-28 to 08-31 with no ZEUS dataset and no substitute venue named, so the mechanism question stays open into the only binary left — QUELL-CV hsCRP topline guided to 2H 2026. The sole company action since the… BVS Bioventus Inc. LOW The M&A leg from the 2026-08-05 unsolicited-proposal disclosure is intact but undated: 17 sessions, no committee update, and price back to the 2026-08-28 close of $13.84, 9.3% under the $15.26 high, with RSI(14) unwound 70.5 → 58.1 → 47.9.… BWIN The Baldwin Insurance Group, Inc. LOW Take-private premium is bleeding while sell-side chases it higher: price slipped to $27.25 (2026-07-17) from $28.41 (2026-07-02) even as KBW went to $31 and JPM to $30. Nothing is signed, and the 2026-07-30 Q2 print (guide $485–490M,… CABA Cabaletta Bio, Inc. LOW Autoimmune CD19 CAR-T reset story, now funded — $225.1M cash at 2026-06-30, runway into mid-2027 — but registrational RESET-Myositis data are guided to mid-2027 and the BLA to 2H27, so no clinical datapoint resolves inside 30 days.… CAL Caleres Inc LOW Q2 was pulled forward one day to 2026-09-09 (announced 2026-09-01), compressing the read into a single session: FY2026 consensus of $1.62 adjusted EPS sits at the top of the company's own $1.40–$1.65 guide, Famous Footwear is guided down… CCXI Churchill Capital Corp XI LOW De-SPAC humanoid pure-play still bleeding premium: $17.07 (2026-08-14) → $14.57 (2026-08-21) → $13.40 (2026-09-04), RSI(14) down to 25.9. The only company-dated item since the 2026-07-14 confidential S-4 is an 2026-08-27… CGC Canopy Growth Corporation LOW The rescheduling binary CGC trades on came and went: the DEA hearing closed 2026-07-15 with no verdict, briefs due 2026-08-17 and the ALJ recommendation undated into H2 2026, likely litigated into 2027. Shares closed $0.89 on 2026-07-24,… CHYM Chime Financial, Inc. LOW Busted-IPO fintech: operations accelerating (Q1 rev +25% to $647M, first GAAP profit, FY guide raised to $2.66–2.69B) but the stock trades ~19% below its $27 IPO and bases near post-IPO lows — a compressed multiple, not an accelerating… CLDX Celldex Therapeutics, Inc. LOW Single-asset binary: the Phase 3 EMBARQ-CSU1/CSU2 topline guided to September/October 2026 is the entire equity, and the window opens within days. The pre-readout re-rating is built and cooling — $39.12 on 2026-08-28, 12.8% under the… CLOV Clover Health Investments, Corp. LOW The $4.00 shelf named as the break has held — a 2026-09-04 close of $4.25 with RSI(14) back to 48.9 from 36.3 — but the leg is now event-dependent: CMS's Eleventh Circuit opening brief leads with a venue argument that could vacate the… CNMD CONMED Corporation LOW Fifty-seven days have passed without a process headline: the 2026-07-10 sale report is still the only leg, and price has started giving ground — $49.32 on 2026-09-04 against the $51.07 close of 2026-08-21, back onto the August shelf. No… CORT Corcept Therapeutics Incorporated LOW Lifyorli oncology launch (approved 2026-03-25, NCCN preferred) re-accelerated the tape to fresh 52-week highs near $92, and the 2026-06-17 Cushing's relacorilant resubmission (~Dec PDUFA) adds second-approval optionality. But a fresh entry… CRTO Criteo S.A. LOW Takeover-premium leg is dead and nothing replaced it: 55 days after the 2026-07-06 Vista/Quinti report no party has confirmed anything, and the freshest headlines are a Huber Research double downgrade (2026-08-24) and a Zacks cut to Strong… CRVS Corvus Pharmaceuticals, Inc. LOW The 2026-08-27 Blood publication put final Phase 1 numbers on soquelitinib — median OS 28.1 months, 9 responses among 24 less-pretreated patients at 200 mg BID — and the tape did not pay for it: $14.16 on 2026-08-28 versus $14.46 on 08-21,… DFTX Definium Therapeutics, Inc. LOW Voyage hit at p<0.0001 on 2026-08-12 and the tape has sold it since: $40.98 on 2026-08-28 versus the $46.14 pre-readout close, RSI 39.8, the $48.45 high untouched. Panorama topline (245 participants, 2:1:2, 50 µg arm) is guided to… DNTH Dianthus Therapeutics, Inc. LOW The August re-rate has rolled over on no news: the last Dianthus disclosure is the 2026-08-04 Q2 print, and the 2026-08-28 close of $105.84 sits 8.7% under the $115.96 high with RSI(14) at 41.9 versus 56.6 a week earlier. Nothing… ELVN Enliven Therapeutics, Inc. LOW Funded, FDA-aligned pre-pivotal CML story whose sell-side re-rating leg is spent: ten houses now publish $64–$82 targets, yet the 2026-08-28 close of $57.86 is 5.4% under the $61.15 high with RSI(14) down to 42.4 from 76.4 on 08-07. No… ERAS Erasca, Inc. LOW FDA Fast Track for ERAS-0015 in metastatic pancreatic (2026-08-24) landed on 16.4x average volume for a -0.17% close; J.P. Morgan then marked to a street-high $33 on 2026-08-27 while the 2026-08-28 close was $18.03 against a $23.5… EVH Evolent Health, Inc LOW The late-June retail bounce has fully unwound — EVH traded ~$5.76 on 2026-07-07, back under the $6.59–6.86 consensus target band and well under Truist's flat $7. Nothing carries the name now except the confirmed 2026-08-06 Q2 print, which… FIG Figma, Inc. LOW Design incumbent re-rated as an AI winner (BofA Buy, $30 PT, 7/7) rather than an AI casualty, yet the stock churns below its 100/200-day moving averages with heavy short interest into its first public earnings print on 8/5 — that print,… FOUR Shift4 Payments, Inc. LOW Payments roll-up at ~$50, a hair above its $46.26 52-week low set on a 2026 guide-down. The Global Blue tax-free-shopping integration ("Shift4 One," launched 2026-07-14) is the transformation leg, but the 2026-07-30 Q2 print is the binary… FWRD Forward Air Corporation LOW Busted-merger workout losing its bid: the +48% June bounce to $14.87 (on a speculative Amazon-bolt-on thesis) has faded ~13% to ~$13, whole-company sale is now reported "unlikely," and the 2026-07-10 chairman exit forfeited… GCO Genesco Inc. LOW The operating turnaround is real but priced, and its one asymmetric leg — the activist proxy fight — lost its teeth: ISS (2026-07-07) backed all nine board directors and urged holders to withhold from the two Radoff/Jumana nominees, so the… GLUE Monte Rosa Therapeutics, Inc. LOW ZEUS (ziltivekimab, MACE HR 0.99) failed on 2026-07-31 and took GLUE −27.16% to $16.52, its worst session on record, because the hsCRP-to-outcomes link under MRT-8102's ASCVD story is exactly what ZEUS could not demonstrate. Platform,… GSHD Goosehead Insurance, Inc. LOW The post-print re-rating rolled over: the 2026-09-04 close of $65.21 gives back most of the August leg after director/10%-owner Serena Jones sold 29,750 Class A shares at $67.56–$70.15 on 2026-08-19/20, the Form 4 signed on the same… HOV Hovnanian Enterprises, Inc. Class A LOW The housing-bill leg is spent — the Act auto-enacted 2026-07-11 and nothing dated has replaced it — yet HOV has re-rated to $137.78 (2026-08-07), 11.8% off the $156.16 high, on no company news. The confirmed 2026-08-20 Q3 print (quarter… HROW Harrow, Inc. LOW Show-me on an H2 ramp with nothing company-dated to resolve it before the ~November Q3 print: the reaffirmed $350–365M FY2026 guide needs the back half to roughly double H1's $114.9M against $292.4M loans payable net, and sell-side FY… IHRT iHeartMedia, Inc. LOW M&A leg is dead — no SiriusXM headline since the 2026-05-29 NYT "stalled" report and the April spike fully round-tripped ($6.33 high → $3.86 on 2026-08-07, -39%). What is left is a binary: Q2 print 2026-08-10 after the close is the first… IMRX Immuneering Corporation LOW Busted-catalyst pancreatic biotech: atebimetinib's 17.3-mo single-arm 1L OS is real, but the Phase 3 binary is mid-2028 and the tape keeps fading post-ASCO ($5.11→$4.32 in two weeks) even as targets climb to $18–$30. Cheap… IRWD Ironwood Pharmaceuticals, Inc. LOW Third straight fortnight of drift: $4.29 on 2026-08-21 to $4.26 on 2026-09-04, RSI 46.8, 21% under the $5.39 high, with the raised 2026-08-06 FY26 guide (revenue $460–485M, adjusted EBITDA above $310M) attracting no new bid. A deleveraging… JBLU JetBlue Airways Corporation LOW Fuel-reversion bull leg broke: Brent re-spiked to ~$86 (Jul 17) on renewed Mideast conflict, reversing the sub-$73 tailwind the whole trade needed. Raymond James (Jul 6) cut to Underperform flagging a Chapter 11 that wipes equity; $9.3B… JELD JELD-WEN Holding, Inc. LOW JELD-WEN's post-2026-08-03 re-rating has stalled: the 2026-09-04 close of $2.30 is back below the 2026-08-28 close of $2.53, RSI(14) has cooled from 71.2 to 61.0, and no company disclosure has landed since the 2026-08-05 analyst updates.… JOBY Joby Aviation, Inc. LOW eVTOL cert story still advancing (FAA TIA testing, 2026 Dubai target) but the trade rolled over: ~$8 testing support, down ~33% since June 1, recovery base gone, CFO sold ~half his stake June 8, consolidation coverage marks sentiment… KOD Kodiak Sciences Inc LOW Binary-catalyst re-run now inside its guided window: DAYBREAK's one-year wet-AMD topline is due before 2026-09-30, and the tape has gone the other way — $35.36 on 2026-09-04, RSI(14) 24.4, a fourth lower step from $42.64 on 2026-07-17, and… LOVE The Lovesac Company LOW The 2026-08-27 notice made the binary real: Q2 FY27 lands before the open on 2026-09-10 against a company bar of $157–166M net sales and −$4M to +$2M adjusted EBITDA. Price closed $16.69 on 2026-09-04, under the 50-day at $16.95 and above… LQDA Liquidia Corporation LOW Post-print rejection intact: LQDA closed $68.66 on 2026-09-04, four cents above the 2026-08-21 break close of $68.62, with RSI(14) at 30.4 and the 2026-09-03 SSc-RP Fast Track absorbed without a new bid. The narrative leg now on offer is… LRMR Larimar Therapeutics, Inc. LOW Single-asset FA regulatory binary sitting on the line that defines it: the week ending 2026-09-04 closed $3.83, 0.8% above the twice-tested $3.80 shelf, after five weeks with no company press release since the 2026-08-04 Q2 update. The… MAZE Maze Therapeutics, Inc. LOW APOL1 kidney proof-of-concept intact and funded into 2029, but the only news since the last note was a conference calendar: the 2026-09-02 release scheduled fireside chats on Sept 9, 10 and 15 and repeated the late-2026/early-2027 HORIZON… MBX MBX Biosciences, Inc. LOW The Q3 commitment landed early — first patient dosed in the pivotal Phase 3 oPTimize trial on 2026-08-27 — and the tape sold it: $66.33 on 08-21 to $61.72 on 09-04, RSI(14) 30.2, 12.7% under the $70.70 high. The compiled consensus stayed… MGM MGM RESORTS INTERNATIONAL LOW Take-private process went live: WSJ reported substantive Diller talks 2026-07-10, MGM seated a special committee mid-July, and the board reportedly views $48.30 as too low — so the trade is now a bump handicap, not a growth story. At… MMYT MakeMyTrip Limited LOW MakeMyTrip's mid-year recovery bounce has stalled: after reclaiming the 200-day near $55, MMYT rolled back to ~$49, below both the 50- and 200-day, straight into an August 3 Q1 FY2027 print where consensus models EPS down ~76% YoY on ~137x… NRIX Nurix Therapeutics, Inc. LOW Roche-partnered BTK degrader holding the post-Phase-3 shelf but running out of dated events: the 2026-09-01 release named four September investor conferences and no medical meeting, so the 09-09/12 SOHO window looks set to pass without… NVEC NVE Corporation LOW The single-quarter re-rate has round-tripped: the 2026-08-28 close of $100.89 lost the $105 gap shelf, RSI(14) is 27.6, and the shares are up 0.8% over three months despite an 81% revenue quarter reported 2026-07-22. No company news or… ODD ODDITY Tech Ltd. LOW Broken compounder with exactly one dated event: the 2026-09-09 pre-market Q2 print. Price ran $13.22 (2026-08-21) to $14.35 (2026-08-28) on no company disclosure since 2026-07-22, leaving it ~30% above the $11.07 consensus target of 10… ORIC Oric Pharmaceuticals, Inc. LOW mCRPC PRC2 story de-risked as rinzimetostat enters registrational Phase 3 (Himalayas-1, 2026-07-14) with Bayer supplying NUBEQA and a J&J-backed enozertinib lung program behind it. But pivotal data is 2028+, so the only near-term mover is… PI Impinj, Inc. LOW Post-correction RAIN RFID recovery has extended to $138.37 (2026-07-17), holding the reclaimed $128 April gap-fill and pressing the $144.57 post-earnings high — but the entire near-term read is the 2026-07-29 Q2 print (guide $103–106M, EPS… PLAY Dave & Buster's Entertainment, Inc. LOW Turnaround narrative dead since the 2026-06-15 comp miss (-5.4%, EPS $0.16 vs ~$0.598); the stock printed a fresh low at $8.72 on 2026-09-04, breaking the $9.40 July floor. The company confirmed Q2 FY2026 results for 2026-09-14 after the… PLTK Playtika Holding Corp. LOW The control-premium leg is dead: the 2026-09-04 weekly close of $2.20 took out the $2.37 level published 2026-08-23, and the strategic review has run five months with no disclosure. What is left is a refinancing stub — $800M of… PRLD Prelude Therapeutics Incorporated LOW Value still hangs on one counterparty decision: Incyte's $100M exercise fee on PRT12396, with the option window running to February 2027. Nothing company-dated has printed since the 2026-08-11 Q2 release and the next 30 days are empty,… QDEL QuidelOrtho Corporation LOW Deal leg is dead and still unresolved: the 2026-06-29 rumor gap was fully retraced by the $13.75 close of 2026-08-10, and the August drift to $14.74 has round-tripped to $13.97 on 2026-09-04 with no company disclosure in between. An… QRVO Qorvo, Inc. LOW Qorvo trades as a fixed-ratio merger spread: 0.960 SWKS plus $32.50 cash. Skyworks' $74.02 close on 2026-09-04 implies $103.56 against Qorvo's $102.84 — about 0.70% gross, the thinnest of this coverage, after the acquirer rallied 12.5% in… QURE uniQure N.V. LOW FDA's 2026-06-17 reversal put AMT-130 on an accelerated-approval path with a Q3 2026 BLA — the narrative is genuinely repaired, but the move is spent: $40.25 (7/17) sits below the $45.50 June offering price with the CEO selling into it on… RARE Ultragenyx Pharmaceutical Inc. LOW The +50% June reset rally round-tripped from ~$33.46 to $28.62 (2026-07-21), parking price back on the breakout shelf ahead of two binary FDA decisions: DTX401 (GSD Ia) PDUFA Aug 23 and UX111 (Sanfilippo A) PDUFA Sep 19. The July 30 Q2… RBLX Roblox Corporation LOW Broken growth compounder: the age-verification rollout throttled DAUs and forced FY26 bookings guidance down to +8-12%; stock is -66% from its $150 high and below the 200-day. The 2026-07-30 Q2 print is the binary — it needs a DAU… RLAY Relay Therapeutics, Inc. LOW The $26–$31 sell-side band is the bull case, but nothing clinical is dated before the year-end ReDiscover-2 enrollment update. RLMD Relmada Therapeutics, Inc. LOW The re-rate narrative failed: the $4.75 March PIPE strike broke on the 2026-08-21 weekly close and the tape kept eroding to $4.43 on 2026-09-04, with no dated clinical event before the year-end 2026 IND. What is left is $217.7M of cash at… RPAY Repay Holdings Corporation LOW The Visa-headline pop has round-tripped — $4.01 on 2026-08-21 back to $3.88 on 2026-09-04 — while the deal file stayed silent: the only company items since are an 2026-08-26 NxtEdge AP partnership and a 2026-09-03 IR hire, leaving… RZLT Rezolute, Inc. LOW The August screener bid fully round-tripped: $5.09 on 2026-08-21 to $4.58 on 2026-09-04, back under the $4.60/$4.61 summer shelf, with no clinical news since 2026-06-17. The registrational upLIFT topline is still guided only to "2H-2026"… SANA Sana Biotechnology, Inc. LOW Type-1-diabetes functional-cure narrative: UP421's no-immunosuppression islet transplant is still producing insulin at 14 months (n=1), de-risking SC451's IND guided "as early as 2026." Rare-disease cell therapy is accelerating, but the… SEER Seer, Inc. LOW The take-private ladder has stalled into a stand-off: the $2.55 Radoff-JEC bid lapsed unanswered on 2026-08-10, and the group's 2026-08-13 release demanding the board disclose an evaluation timeline has drawn no company reply through the… SPRB Spruce Biosciences, Inc. LOW Ultra-rare ERT filing story cooling: after the 2026-08-24 pre-BLA clearance the news flow stopped, and the shares drifted from the 2026-08-28 close of $60.78 to $57.93 on 2026-09-04 with RSI(14) back to 58.1 from 77.6. Nothing… SPRY ARS Pharmaceuticals, Inc. LOW Single-product epinephrine name whose one catalyst — a July no-prior-auth formulary add for neffy — came and went unpaid; the stock has since broken its old $6.66 52-week low to fresh lows near $6. The neffy ramp is real but the access… STAA STAAR Surgical Company LOW The re-rating leg failed and has not been re-bid: after the 2026-08-21 weekly close at $23.14 broke the $23.50 shelf, ten sessions produced only $23.47 on 2026-09-04 and a 2026-09-02 CTO appointment the tape ignored. What is left is a… STM STMicroelectronics N.V. LOW The June AI-data-center re-rating has failed its retest: $62.06 on 2026-07-17 is -22% from the 2026-06-22 high of $79.82 and back under the early-June breakout base, with a $1.5B convertible overhang and a 7% selloff that ignored a BofA… STRO Sutro Biopharma, Inc. LOW Single-asset binary now inside its own catalyst window: the STRO-004 (DAR8 Tissue Factor exatecan ADC) Phase 1 readout was guided "mid-2026" and that window is expiring undated. Price has gone flat at ~$29.7 for four weeks after the June… TENX Tenax Therapeutics, Inc. LOW Post-failure rebuild, not a rescue: the 2026-08-29 ESC late-breaker put the prespecified sub-median-6MWD subgroup (n=119) at +26.3m vs placebo (nominal p=0.0112), and Adar1 disclosed buying 1m+ shares at an average $1.77 on 2026-08-25,… TLRY Tilray Brands, Inc. LOW Reform binary spent without resolving: the DEA hearing closed 2026-07-15 with only a 2026-08-17 briefing deadline and no ALJ timeline, so Schedule III is now an open-ended administrative process. TLRY printed a fresh 52-week low of $4.20… TMC TMC the metals company Inc. LOW The deep-sea-mining reshoring leg is broken: TMC has cut through the $3.93 prior 52-week low to a fresh $3.57 low near $3.74, roughly -67% from the $11.35 high, with no bid and no near-term catalyst. The decisive NOAA license decision is… TSHA Taysha Gene Therapies, Inc. LOW De-risking is behind the stock and the calendar in front of it is empty: after the clean 2026-06-22 data and the $6.00 June raise, no company-dated event lands before the ~November Q3 update, and the tape has drifted to a $5.60 close on… UI Ubiquiti Inc. LOW Broken parabola gone flat: six weeks of $530–$570 chop after the May 8 print (GM 47.0%, rev +18.7%, but EPS $3.88 vs ~$4.42 whisper) with zero scheduled catalyst until the Q4 FY26 report on 2026-08-21. Fundamentals intact, tape dead,… VECO Veeco Instruments Inc. LOW Merger-arb tracking stock for Axcelis: fixed 0.3575 ACLS/VECO, both votes cleared 2026-02-06, only China SAMR remains before the 2026-09-30 outside date. ACLS's slide to ~$134 de-pegged VECO to a premium over the exchange ratio (~$48) —… VERI Veritone, Inc. LOW The growth story broke on the 2026-08-13 guide cut to $100–115M from $130–145M; what trades now is $45.6M of 1.75% converts maturing 2026-11-15 against $12.7M of cash at 2026-06-30 and disclosed going-concern doubt. The stock bounced from… VIR Vir Biotechnology, Inc. LOW Q2 (2026-08-05) printed $238.9M revenue and $0.47 diluted EPS on Astellas upfront recognition — an accounting swing, and the tape read it as one: $9.24 on 2026-08-14, still under the $10.36 Astellas equity strike, with Morgan Stanley and… VKTX Viking Therapeutics, Inc. LOW The stock has round-tripped its ECO move — $32.16 on 2026-08-28, 23.7% below the $42.13 high, the ~$34 line gone since 2026-08-14. The only company-guided 2026 event left is the VK2735 maintenance readout, a Phase 1 whose weight endpoint… WGS GeneDx Holdings Corp. LOW Busted-growth genomics name; the recovery off the −49% May guide-cut crash has stalled in the low-$60s, below the $74.83 200-day. The confirmed Aug 3 Q2 print (blended ARR vs the ~$3,300 baseline) is the binary — the same day as the… WING Wingstop Inc. LOW Two analyst target cuts in ten days (Wells Fargo to $170, DA Davidson to $200) into the 2026-07-29 Q2 print signal de-risking ahead of the H2 comp-turn binary; a ~50% relief bounce off the $116.35 low is unproven, and the print — not… XENE Xenon Pharmaceuticals Inc. LOW The $62 consolidation shelf failed at the 2026-08-28 weekly close of $59.99, and two dated events now sit inside 30 days: the EEC oral presentation of X-TOLE2 on 2026-09-07 and the guided Q3 FOS NDA submission by 2026-09-30. Neither is an… ZVRA Zevra Therapeutics, Inc. LOW The June patent re-rating fully reversed: EMA's CHMP issued a negative opinion on arimoclomol's EU application 2026-07-24 (efficacy not proven), and ZVRA gapped ~24% to the high-$9s, cutting through the $11.50 base. EU expansion is now…